𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritis

✍ Scribed by Ewa Bryl; Abbe N. Vallejo; Eric L. Matteson; Jacek M. Witkowski; Cornelia M. Weyand; Jorg J. Goronzy

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
218 KB
Volume
52
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti–tumor necrosis factor therapy incre
Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis
✍ Anca Irinel Catrina; Erik af Klint; Sofia Ernestam; Sergiu-Bogdan Catrina; Dimit 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 1 views

## Abstract ## Objective Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF)–blocking agents, including etanercept and infliximab, has resulted in reductions in the radiographic progression of RA. However, the exact mechanism by which this protection occurs has not been determi

Antiangiogenic effects of anti–tumor nec
Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritis
✍ Juan D. Cañete; José L. Pablos; Raimon Sanmartí; Carmen Mallofré; Sara Marsal; J 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

## Abstract ## Objective Neovascularization, with an increased number of synovial vessels with a characteristic morphology, seems to contribute to the progression of psoriatic arthritis (PsA). Accordingly, angiogenesis may be an important therapeutic target in PsA. The aim of this study was to ana

Anti-tumor necrosis factor α switching i
Anti-tumor necrosis factor α switching in rheumatoid arthritis and juvenile chronic arthritis
✍ Favalli, Ennio Giulio ;Arreghini, Marco ;Arnoldi, Cristina ;Panni, Benedetta ;Ma 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views

COPD ϭ chronic obstructive pulmonary disease. 300 Letters \* RA ϭ rheumatoid arthritis; JRA ϭ juvenile rheumatoid arthritis; ESR ϭ erythrocyte sedimentation rate; CRP ϭ C-reactive protein; VAS ϭ visual analog scale; GH ϭ general health; DAS28 ϭ Disease Activity Score in 28 joints; HAQ ϭ Health Asses

Anti–tumor necrosis factor α therapy and
Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer
✍ Deborah P. M. Symmons; Alan J. Silman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

The authors are the principal investigators of the British Society of Rheumatology (BSR) Biologics Register. The BSR receives financial support for the Register from the manufacturers of biologic agents currently licensed for use in the treatment of patients with inflammatory rheumatic diseases. The